Current Status of Stem Cell Treatment for Type I Diabetes Mellitus
- 33 Downloads
Diabetes mellitus is a major health concern in current scenario which has been found to affect people of almost all ages. The disease has huge impact on global health; therefore, alternate methods apart from insulin injection are being explored to cure diabetes. Therefore, this review mainly focuses on the current status and therapeutic potential of stem cells mainly mesenchymal stem cells (MSCs) for Type 1 diabetes mellitus in preclinical animal models as well as humans.
Current treatment for Type 1 diabetes mellitus mainly includes use of insulin which has its own limitations and also the underlying mechanism of diseases is still not explored. Therefore, alternate methods to cure diabetes are being explored. Stem cells are being investigated as an alternative therapy for treatment of various diseases including diabetes. Few preclinical studies have also been conducted using undifferentiated MSCs as well as in vitro MSCs differentiated into β islet cells.
These stem cell transplant studies have highlighted the benefits of MSCs, which have shown promising results. Few human trials using stem cells have also affirmed the potential of these cells in alleviating the symptoms.
Stem cell transplantation may prove to be a safe and effective treatment for patients with Type 1 diabetes mellitus.
KeywordsDiabetes mellitus Stem cells In vitro differentiation Bone marrow
The authors are grateful to the Datt Mediproducts Pvt. Ltd. for supporting their current research. We sincerely thank Dr. Rajan Datt for valuable scientific discussion.
Compliance with ethical standards
Conflicts of interest
The authors declare that they have no conflict of interests.
There are no animal expreiments carried out for this article.
- 2.IDF Diabetes Atlas, 5th edition. International Diabetes Federation. 2011. https://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/20:atlas-5th-edition.html.
- 4.DeFronzo RA. Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev. 1997;5:177–266.Google Scholar
- 14.Mohanty S, Jain KG, Nandy SB, Kakkar A, Kumar M, Dinda AK, et al. Iron oxide labeling does not affect differentiation potential of human bone marrow mesenchymal stem cells exhibited by their differentiation into cardiac and neuronal cells. Mol Cell Biochem. 2018. https://doi.org/10.1007/s11010-018-3309-9.PubMedGoogle Scholar
- 16.Gao R, Ustinov J, Pulkkinen MA, Lundin K, Korsgren O, Otonkoski T. Characterization of endocrine progenitor cells and critical factors for their differentiation in human adult pancreatic cell culture. Diabetes. 2003;52:2007–15.Google Scholar
- 64.Gao F, Wu DQ, Hu YH, Jin GX. Extracellular matrix gel is necessary for in vitro cultivation of insulin producing cells from human umbilical cord blood derived mesenchymal stem cells. Chin Med J (Engl). 2008;121:811–8.Google Scholar
- 68.Ezquer F, Ezquer M, Contador D, Ricca M, Simon V, Conget P. The antidiabetic effect of mesenchymal stem cells is unrelated to their transdifferentiation potential but to their capability to restore Th1/Th2 balance and to modify the pancreatic microenvironment. Stem Cells. 2012;30:1664–74.CrossRefPubMedGoogle Scholar
- 78.Cai J, Wu Z, Xu X, Liao L, Chen J, Huang L, et al. Umbilical cord mesenchymal stromal cell with autologous bone marrow cell transplantation in established type 1 diabetes: a pilot randomized controlled open-label clinical study to assess safety and impact on insulin secretion. Diabetes Care. 2016;39:149–57.CrossRefPubMedGoogle Scholar
- 93.Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009;54:2277–86.CrossRefPubMedPubMedCentralGoogle Scholar